Vaquero-Siguero N., Georgakopoulos N., Puschhof. MC., Jackstadt R. et al. TROP2 targeting reveals therapy-driven cell state dynamics and vulnerabilities in colorectal cancer. Nature 2026 (in press)
Category: Publication
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma
Peng J, Yang J, Antonopoulou G. et al. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Nat Commun. 2026 (PMID: 41651844)
Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience
Hlevnjak M, Heublein S, Thewes V. et al. Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience. Int J Cancer. 2026 (PMID: 41170836)
LiMeTrack: A lightweight biosample management platform for the multicenter SATURN3 consortium
Heyl F., Gassenschmidt J, Heine L, Voigt F., Kleesiek J., Stegle O., Siveke JT., Boerries M., Schwarz RF., Godfrey L. LiMeTrack: A lightweight biosample management platform for the multicenter SATURN3 consortium (under review). bioRxiv 2025. https://doi.org/10.1101/2025.09.01.25334868
PhytClust: efficient and optimalnode clustering in phylogenetic trees
Ganesan K., Billard E., Schwarz RF. PhytClust: efficient and optimal node clustering in phylogenetic trees (under review). bioRxiv 2025. https://doi.org/10.64898/2025.12.11.693738
Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer
Rödel F, Fleischmann M, Diefenhardt M, Dapper H, Hoffmann A, Rödel C, Martin D, Fokas E. Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer. Nat Rev Clin Oncol 2025 (PMID: 40360682).
(68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial
Kessler L, Hirmas N, Pabst KM, et al. (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial (PMID: 37973185). J Nucl Med. 2023.
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer
Veghini L, Pasini D, Fang R, et al. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer (PMID: 39627211). Nat Commun. 2024.
1525P – Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Siveke J.T., Dorman K., Siegler G.M., Seufferlein T., Trojan J., Waldschmidt D.T., Koenig A.O., Schipp D., Liffers S.T., Kunzmann V. 1525P – Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study. Conference contribution (ESMO 2024).
Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma
Papargyriou A, Najajreh M, Cook DP, et al. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma (PMID: 39658630). Nat Biomed Eng. 2024.
